May 02, 2022
3 min watch
Save
VIDEO: Tarsus announces positive phase 3 data for TP-03 for Demodex blepharitis
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this Healio Video Perspective, Bobak Azamian, MD, PhD, CEO and co-founder of Tarsus Pharmaceuticals, discusses topline data from the Saturn-2 phase 3 study of TP-03 for the treatment of Demodex blepharitis.
“This study hit all of the primary and secondary endpoints with very high statistical significance,” Azamian said. “The primary endpoint, to remind everyone, is a complete collarette cure, a complete elimination of collarettes across the entire eyelid, which is the key sign ... for Demodex blepharitis, and Saturn-2 showed this in 56% of patients, a really remarkable result.”
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.